Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01937507 · ClinicalTrials.gov registry record · Phase 2
Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer
A Phase 2 study, sponsored by Western Regional Medical Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT01937507: Clinical Trial Phase 2 study, sponsored by Western Regional Medical Center.
NCT01937507 is a Phase 2 study that was terminated before completion, run by Western Regional Medical Center. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01937507, a Phase 2 study, was terminated before completion, sponsored by Western Regional Medical Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Deliver oxliplatin and 5-FU via HAI to breast cancer patients with liver-only or liver-predominant metastases who have failed at least one line of systemic chemotherapy in metastatic setting.
Interventions
- DRUG HAI with FOLFOX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01937507
The ClinicalTrials.gov registry entry for NCT01937507 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Western Regional Medical Center, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HAI with FOLFOX is the first listed.
NCT01937507 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01937507 about?
NCT01937507 is a clinical study titled "Hepatic Artery Infusion With FOLFOX in Liver Metastasis From Breast Cancer". Deliver oxliplatin and 5-FU via HAI to breast cancer patients with liver-only or liver-predominant metastases who have failed at least one line of systemic chemotherapy in metastatic setting.
What is the current status of trial NCT01937507?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2012-12. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01937507?
The interventions under investigation include: HAI with FOLFOX (DRUG).
Who is sponsoring clinical trial NCT01937507?
This trial is sponsored by Western Regional Medical Center, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.